Before BCR and Bcl-2 inhibitors were found to be effective and started to be employed in treating high-risk CLL, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was the only curative option for the patients with recurrent or refractory CLL (138). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.